postmenopausal osteoporosis
Endocrinology · 2005–2007
7decisions
2medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| Ibandronic Acid established postmenopausal osteoporosis in patients with fracture due to minimal trauma | Mar 2007 | Recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Mar 2007 | Recommended with restriction | no section in document |
| Ibandronic Acid Initial treatment as the sole anti-resorptive agent for established postmenopausal osteoporosis in patients with fracture due to minimal trauma; Continuing… | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| strontium ranelate Treatment of post-menopausal osteoporosis to reduce the risk of fracture in patients with established osteoporosis and fracture due to minimal trauma. | Jul 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.